<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208103</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0626</org_study_id>
    <secondary_id>NCI-2018-01828</secondary_id>
    <secondary_id>NCI-2011-00470</secondary_id>
    <secondary_id>2009-0626</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01208103</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma</brief_title>
  <official_title>Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well bevacizumab given with capecitabine and oxaliplatin work
      in treating participants with small bowel or ampulla of Vater adenocarcinoma that has spread
      to other places in the body. Monoclonal antibodies, such as bevacizumab, may interfere with
      the ability of tumor cells to grow and spread. Drugs using in chemotherapy, such as
      capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells,
      either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. Giving bevacizumab, capecitabine, and oxaliplatin may work better in treating
      participants with small intestinal or ampulla of Vater adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the progression-free survival (PFS) at six months for patients with advanced
      adenocarcinoma of the small bowel (small intestine) or ampulla of Vater treated with
      capecitabine, oxaliplatin (CAPOX) and bevacizumab.

      SECONDARY OBJECTIVES:

      I. To determine the response rate (RR) for CAPOX and bevacizumab. II. To determine the
      overall progression free survival for CAPOX and bevacizumab.

      III. To determine the overall survival (OS) for CAPOX and bevacizumab. IV. To determine the
      toxicity of CAPOX and bevacizumab.

      OUTLINE:

      Participants receive oxaliplatin via central venous catheter (CVC) over 2 hours and
      bevacizumab intravenously (IV) over 30-90 minutes on day 1. Participants also receive
      capecitabine orally (PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, participants are followed up at 10 and 30 days, and then
      every 3 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2011</start_date>
  <completion_date type="Actual">March 7, 2018</completion_date>
  <primary_completion_date type="Actual">March 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Progression-free Survival (PFS) at Six Months</measure>
    <time_frame>6 months</time_frame>
    <description>A Bayesian sequential monitoring design will be used. PFS will be estimated using the Kaplan-Meier method.The length of time interval in months from date of first treatment, during and after the treatment a participant lives without progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Response Rate (RR) for CAPOX and Bevacizumab</measure>
    <time_frame>39 months</time_frame>
    <description>Complete response + Partial response using RECIST 1.1 (Response Evaluation Criteria in Solid Tumor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Overall PFS for CAPOX and Bevacizumab</measure>
    <time_frame>39 months</time_frame>
    <description>Time interval in months from date of first treatment until the date of first documented progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Overall Survival (OS) for CAPOX and Bevacizumab</measure>
    <time_frame>39 months</time_frame>
    <description>The length of time interval in months from date of first treatment until the date of death or lost follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>39 months</time_frame>
    <description>Toxicity was graded according to the NCI Common terminology Criteria for Adverse Events (CTCAE) 4.0 except for neurosensory and skin toxicity. Neurosensory toxicity was graded according to the Neurologic Toxicity Scale for Oxaliplatin Dose Adjustments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ampulla of Vater Adenocarcinoma</condition>
  <condition>Small Intestinal Adenocarcinoma</condition>
  <condition>Stage III Ampulla of Vater Cancer AJCC v8</condition>
  <condition>Stage III Small Intestinal Adenocarcinoma AJCC v8</condition>
  <condition>Stage IIIA Ampulla of Vater Cancer AJCC v8</condition>
  <condition>Stage IIIA Small Intestinal Adenocarcinoma AJCC v8</condition>
  <condition>Stage IIIB Ampulla of Vater Cancer AJCC v8</condition>
  <condition>Stage IIIB Small Intestinal Adenocarcinoma AJCC v8</condition>
  <condition>Stage IV Ampulla of Vater Cancer AJCC v8</condition>
  <condition>Stage IV Small Intestinal Adenocarcinoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (oxaliplatin, bevacizumab, capecitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oxaliplatin via CVC over 2 hours and bevacizumab IV over 30-90 minutes on day 1. Participants also receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oxaliplatin, bevacizumab, capecitabine)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (oxaliplatin, bevacizumab, capecitabine)</arm_group_label>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given CVC</description>
    <arm_group_label>Treatment (oxaliplatin, bevacizumab, capecitabine)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed adenocarcinoma of the small bowel or
             ampulla of Vater

          -  Prior adjuvant chemotherapy (including fluorouracil [5-FU], capecitabine, and
             oxaliplatin) for the treatment of adenocarcinoma of the small bowel or ampulla of
             Vater is allowed if completed &gt;= 52 weeks prior to first dose of study treatment

          -  Prior capecitabine or 5-FU administered as a radio-sensitizing agent concurrently with
             external beam radiotherapy is allowed

          -  Patients must have metastatic disease

          -  A minimum of 4 weeks must have elapsed from completion of any prior chemotherapy or
             radiotherapy or surgery and the start date of study therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Absolute neutrophil count (ANC) &gt;= 1,500/ul

          -  Platelets &gt;= 100,000/ul

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN)

               -  In patients with known Gilbert's syndrome direct bilirubin =&lt; 1.5 x ULN will be
                  used as organ function criteria, instead of total bilirubin

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) &lt; 3 x
             ULN

          -  Calculated creatinine clearance (CrCl) &gt; 50 cc/min (calculated using the Cockcroft and
             Gault formula)

          -  Negative serum or urine pregnancy test in women with childbearing potential (defined
             as not post-menopausal for 12 months or no previous surgical sterilization), within
             one week prior to initiation of treatment

          -  Patients must sign an Informed Consent and Authorization indicating that they are
             aware of the investigational nature of this study and the known risks involved

          -  The effects of the combination of CAPOX and bevacizumab on the developing fetus are
             unknown. For this reason, women of childbearing potential and men must agree to use
             adequate contraception (hormonal or barrier method of birth control) prior to study
             entry, for the duration of study participation, and for six months following the
             completion of therapy. Should a woman become pregnant while participating in this
             study, she should inform her treating physician immediately

          -  Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with oxaliplatin or capecitabine or bevacizumab,
             breast feeding must be discontinued

        Exclusion Criteria:

          -  Patients who have received prior chemotherapy for their metastatic disease are
             excluded. Chemotherapy if given as a radiation-sensitizer is allowed

          -  Patients may not be receiving any other investigational agents nor have received any
             investigational drug 28 days prior to enrollment

          -  Known history of dihydropyrimidine (DPD) deficiency

          -  Peripheral neuropathy of grade 3 or greater by Common Terminology Criteria for Adverse
             Events (CTCAE) 4.0

          -  Gastrointestinal tract disease resulting in an inability to take oral medication or a
             requirement for IV alimentation

          -  Because of the interaction between coumadin and capecitabine, patients taking
             therapeutic doses of coumadin-derivative anticoagulants are not eligible. Low-dose
             coumadin (e.g. 1 mg PO per day) in patients with in-dwelling venous access devices is
             allowed but increased frequency of international normalized ratio (INR) monitoring is
             recommended

          -  Prior treatment with bevacizumab or known hypersensitivity to any component of
             bevacizumab

          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt;140 mmHg
             and/or diastolic blood pressure &gt; 90 mmHg)

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  New York Heart Association (NYHA) grade II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina within 6 months prior to day 1

          -  History of stroke or transient ischemic attack within 6 months prior to day 1.

          -  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
             recent peripheral arterial thrombosis) within 6 months prior to day 1

          -  History of hemoptysis (&gt;= 1/2 teaspoon of bright red blood per episode) within 1 month
             prior to day 1

          -  History of abdominal fistula or gastrointestinal perforation which must have resolved
             at least 6 months prior to day 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 1 or anticipation of need for major surgical procedure during the course
             of the study

          -  Core biopsy or other minor surgical procedure excluding placement of a vascular access
             device, within 7 days prior to day 1

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Proteinuria at screening as demonstrated by either (1) urine protein:creatinine (UPC)
             ratio of &gt;= 1.0 or (2) urine dipstick for proteinuria &gt;= 2+ (patients discovered to
             have &gt;/= 2+ proteinuria on dipstick urinalysis should undergo a 24 hour urine
             collection and must demonstrate =&lt; 1g of protein in 24 hours to be eligible)

          -  Known central nervous system (CNS) disease, except for treated brain metastasis.
             Treated brain metastases are defined as having no evidence of progression or
             hemorrhage after treatment and no ongoing requirement for dexamethasone, as
             ascertained by clinical examination and brain imaging (magnetic resonance imaging
             [MRI] or computed tomography [CT]) during the screening period. Anticonvulsants
             (stable dose) are allowed. Treatment for brain metastases may include whole brain
             radiotherapy (WBRT), radiosurgery (RS; gamma knife, linear accelerator [LINAC], or
             equivalent) or a combination as deemed appropriate by the treating physician

          -  Patients with CNS metastases treated by neurosurgical resection or brain biopsy
             performed within 3 months prior to day 1 will be excluded

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study other than this study

          -  Pregnancy (positive pregnancy test) or lactation

          -  Active malignancy, other than superficial basal cell and superficial squamous (skin)
             cell, or carcinoma in situ of the cervix, within last five years

          -  Inability to comply with study and/or follow-up procedures

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, or psychiatric illness/social
             situations that would limit adherence with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Overman</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <results_first_submitted>November 5, 2019</results_first_submitted>
  <results_first_submitted_qc>January 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT01208103/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>August 2011 to November 2014. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
          <description>Capecitabine 750 mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
          <description>Capecitabine 750 mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="42" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Progression-free Survival (PFS) at Six Months</title>
        <description>A Bayesian sequential monitoring design will be used. PFS will be estimated using the Kaplan-Meier method.The length of time interval in months from date of first treatment, during and after the treatment a participant lives without progression.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
            <description>Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Panitumumab 9 mg/kg IV over 60 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression-free Survival (PFS) at Six Months</title>
          <description>A Bayesian sequential monitoring design will be used. PFS will be estimated using the Kaplan-Meier method.The length of time interval in months from date of first treatment, during and after the treatment a participant lives without progression.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="52" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Response Rate (RR) for CAPOX and Bevacizumab</title>
        <description>Complete response + Partial response using RECIST 1.1 (Response Evaluation Criteria in Solid Tumor)</description>
        <time_frame>39 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
            <description>Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Response Rate (RR) for CAPOX and Bevacizumab</title>
          <description>Complete response + Partial response using RECIST 1.1 (Response Evaluation Criteria in Solid Tumor)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Overall PFS for CAPOX and Bevacizumab</title>
        <description>Time interval in months from date of first treatment until the date of first documented progression</description>
        <time_frame>39 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
            <description>Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Overall PFS for CAPOX and Bevacizumab</title>
          <description>Time interval in months from date of first treatment until the date of first documented progression</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="4.9" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Overall Survival (OS) for CAPOX and Bevacizumab</title>
        <description>The length of time interval in months from date of first treatment until the date of death or lost follow-up</description>
        <time_frame>39 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
            <description>Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Overall Survival (OS) for CAPOX and Bevacizumab</title>
          <description>The length of time interval in months from date of first treatment until the date of death or lost follow-up</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="9.2" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Toxicity was graded according to the NCI Common terminology Criteria for Adverse Events (CTCAE) 4.0 except for neurosensory and skin toxicity. Neurosensory toxicity was graded according to the Neurologic Toxicity Scale for Oxaliplatin Dose Adjustments.</description>
        <time_frame>39 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
            <description>Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Toxicity was graded according to the NCI Common terminology Criteria for Adverse Events (CTCAE) 4.0 except for neurosensory and skin toxicity. Neurosensory toxicity was graded according to the Neurologic Toxicity Scale for Oxaliplatin Dose Adjustments.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed up to 67 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Capecitabine + Oxaliplatin</title>
          <description>Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Panitumumab 9 mg/kg IV over 60 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.3</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Peripheral sensor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pnuemonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Overman/Gastrointestinal Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-4317</phone>
      <email>MOverman@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

